The von Hhippel-Lindau protein interacts with heteronuclear ribonucleoprotein A2 and regulates its expression

被引:55
作者
Pioli, PA
Rigby, WFC
机构
[1] Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA
[2] Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03756 USA
[3] Vet Adm Med Ctr, White River Jct, VT 05009 USA
关键词
D O I
10.1074/jbc.M105391200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The product of the von Hippel-Lindau (VHL) tumor suppressor gene, pVHL, functions as a ubiquitin-protein isopeptide ligase in regulating HIF-1 protein turnover, thus accounting for the increased transcription of hypoxia-inducible genes that accompanies VHL mutations. The increased vascular endothelial growth factor mRNA stability in cells lacking pVHL has been hypothesized to be due to a similar regulation of an RNA-binding protein. We report the expression of the GLUT-1 3'-untranslated region RNA-binding protein, heteronuclear ribonucleoprotein (hnRNP) A2, is specifically increased in pVHL-deficient cell lines. Enhanced hnRNP A2 expression was apparent in all cell fractions, including polysomes, where a similar modest effect on hnRNP L (a GLUT-1 and VEGF 3'-untranslated region-binding protein), was seen. Steady state levels of hnRNP A2 m-RNA were unaffected. Regulation of hnRNP A2 levels correlated with the ability of pVHL to bind elongin C. Proteasome inhibition of cells expressing wild type pVHL selectively increased cytoplasmic hnRNP A2 levels to that seen in pVHL-deficient cells. Finally, an in vivo interaction between pVHL and hnRNP A2 was demonstrated in both the nucleus and the cytoplasm. Collectively, these data indicate that hnRNP A2 expression is regulated by pVHL in a manner that is dependent on elongin C interactions as well as functioning proteasomes.
引用
收藏
页码:40346 / 40352
页数:7
相关论文
共 67 条
[41]  
Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957
[42]   The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity [J].
Lisztwan, J ;
Imbert, G ;
Wirbelauer, C ;
Gstaiger, M ;
Krek, W .
GENES & DEVELOPMENT, 1999, 13 (14) :1822-1833
[43]   Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2 [J].
Lonergan, KM ;
Iliopoulos, O ;
Ohh, M ;
Kamura, T ;
Conaway, RC ;
Conaway, JW ;
Kaelin, WG .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :732-741
[44]  
Los M, 1996, LAB INVEST, V75, P231
[45]  
Mathias N, 1996, MOL CELL BIOL, V16, P6634
[46]   The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [J].
Maxwell, PH ;
Wiesener, MS ;
Chang, GW ;
Clifford, SC ;
Vaux, EC ;
Cockman, ME ;
Wykoff, CC ;
Pugh, CW ;
Maher, ER ;
Ratcliffe, PJ .
NATURE, 1999, 399 (6733) :271-275
[47]   Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein [J].
Ohh, M ;
Park, CW ;
Ivan, N ;
Hoffman, MA ;
Kim, TY ;
Huang, LE ;
Pavletich, N ;
Chau, V ;
Kaelin, WG .
NATURE CELL BIOLOGY, 2000, 2 (07) :423-427
[48]   The von Hippel-Lindau tumour suppressor protein: new perspectives [J].
Ohh, M ;
Kaelin, WG .
MOLECULAR MEDICINE TODAY, 1999, 5 (06) :257-263
[49]   The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins [J].
Pause, A ;
Lee, S ;
Worrell, RA ;
Chen, DYT ;
Burgess, WH ;
Linehan, WM ;
Klausner, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2156-2161
[50]   A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor [J].
Schoenfeld, A ;
Davidowitz, EJ ;
Burk, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8817-8822